
|Articles|August 4, 2003
Many could benefit from BPH drug with unique technology
Men with benign prostatic hyperplasia (BPH) will soon have a therapeutic option that uses a unique drug delivery system. The FDA recently approved alfuzosin (UroXatral, Sanofi-Synthelabo) extended-release tablets for the treatment of the signs and symptoms of BPH. Alfuzosin is not indicated for the treatment of hypertension. The manufacturer expects alfuzosin to be available in pharmacies sometime in the second half of 2003.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Rise in IPD Calls for Development of More Pneumococcal Vaccines
2
Disparities Emerge During COVID-19 Vaccine Shortage for Rural Patients
3
Following COVID-19 Pandemic, Cardiovascular Health Trends Suggest Increased Physical Activity
4
Infants Without Access to Maternal Care Exhibit High Mortality Risk
5












































































































































